• Nature

  • Source

    Wheat germ
  • Amino Acid Sequence
    • Species

    • Sequence

    • Amino acids

      101 to 199
    • Tags

      GST tag N-Terminus


Our Abpromise guarantee covers the use of ab159917 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications


    Western blot

  • Form

  • Additional notes

    Protein concentration is above or equal to 0.05 mg/ml.

     This product was previously labelled as EPM2A', 'EPM2A, isoform 9


  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    pH: 8.00
    Constituents: 0.31% Glutathione, 0.79% Tris HCl

General Info

  • Alternative names

    • Epilepsy progressive myoclonus type 2 Lafora disease (laforin)
    • Epilepsy progressive myoclonus type 2A Lafora disease (laforin)
    • EPM2
    • Epm2a
    • Epm2a gene
    • Lafora PTPase
    • Laforin
    • LAFPTPase
    • LD
    • LDE
    • MELF
    • RP3-466P17.2
    see all
  • Function

    Dual specificity protein phosphatase. May be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules (polyglucosans). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Forms a complex with NHLRC1/malin and HSP70 and this complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1.
  • Tissue specificity

    Expressed in heart, skeletal muscle, kidney, pancreas and brain. Isoform 4 is also expressed in the placenta.
  • Involvement in disease

    Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2 (EPM2) [MIM:254780]; also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. EPM2 occurs worldwide, but it is particularly common in the mediterranean countries of southern Europe and northern Africa, in southern India and in the Middle East. At the cellular level, it is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle. Among other conditions involving polyglucosans, EPM2 is unique in that the inclusions are in neuronal dendrites but not axons and the forming polyglucosan fibrils are associated with the endoplasmic reticulum.
  • Sequence similarities

    Belongs to the protein-tyrosine phosphatase family.
    Contains 1 CBM20 (carbohydrate binding type-20) domain.
    Contains 1 tyrosine-protein phosphatase domain.
  • Post-translational

    Polyubiquitinated by NHLRC1/malin.
    Phosphorylation on Ser-25 by AMPK affects the phosphatase activity of the enzyme and its ability to homodimerize and interact with NHLRC1, PPP1R3C or PRKAA2.
  • Cellular localization

    Cytoplasm; Cytoplasm. Nucleus; Endoplasmic reticulum. Cell membrane. Nucleus. Also found in the nucleus; Endoplasmic reticulum. Cell membrane. Primarily associated with polyribosomes at the endoplasmic reticulum, also found at the plasma membrane and Cytoplasm. Under glycogenolytic conditions localizes to the nucleus.
  • Information by UniProt


  • ab159917 on a 12.5% SDS-PAGE stained with Coomassie Blue.


ab159917 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab159917.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up